The company plans a clinical trial for its CIL001 tinnitus drug candidate at Massachusetts General Hospital and will triple preclinical capacity through its partnership with CBSET. Cilcare , a French-US biopharmaceutical company, announced a series of investments in the United States, including plans for a clinical trial of its tinnitus drug candidate, CIL001, and a significant expansion of its preclinical research...
✦ Clinical Takeaway ✦
No actionable change; CIL001 is a drug candidate just entering US clinical trials and is years away from any approved clinical use.
✦ Why It Matters ✦
Tinnitus has no FDA-approved pharmacological treatment, making any credible drug entering human trials a significant milestone for the field.
✦ Key Points ✦
- 01Cilcare is launching a US clinical trial for its tinnitus drug candidate CIL001 at Massachusetts General Hospital.
- 02